U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07793019) titled 'IBI3042 Study in Healthy Participants and Overweight or Obese Participants' on Aug. 20.
Brief Summary: This is a Phase 1 study of IBI3042, an investigational oral medicine being developed as a potential treatment for overweight and obesity. The study has two parts. Part A will evaluate single doses of IBI3042 in healthy adults. Part B will evaluate repeated doses for 13 weeks in adults with overweight or obesity. The main goal is to assess the safety and tolerability of IBI3042. The study will also evaluate how IBI3042 is processed in the body and explore its effects on body weight and other metabolic measures. Some participants wil...